Scenario: 2021 patient presents with metastatic prostate adenocarcinoma to the bones, receiving Xgeva.
Question: Would you code the Xgeva to Hormone therapy?
Rationale: SEER*Rx Interactive Antineoplastic Drugs Database https://seer.cancer.gov/seertools/seerrx/
PLEASE SEE IMPORTANT CODING INFORMATION IN REMARKS FIELD
IMPORTANT CODING NOTE (JULY 12, 2013): This drug was approved by the FDA on June 13, 2013 to treat unresectable giant cell tumors of the bone in both adults and skeletally mature adolescents. If this drug is being prescribed to treat this type of tumor, code as BRM/Immunotherapy. For all other conditions listed in the November release information below, do not code, the drug is considered ancillary.